Loading
A phase 1/2 trial of B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell in multiple myeloma, run by Shanghai AbelZeta Ltd., now recruiting.
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05521802 by Shanghai AbelZeta Ltd., with 92 participants planned, started 2022-11-11 and due to reach its primary completion in 2024-07. Interventions recorded: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai AbelZeta and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/